Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $5.67 Consensus PT from Analysts

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been given an average rating of “Moderate Buy” by the five brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $5.67.

Separately, HC Wainwright lowered their price objective on Karyopharm Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, March 1st.

Karyopharm Therapeutics Trading Up 2.0 %

Karyopharm Therapeutics stock opened at $1.51 on Tuesday. The company has a market capitalization of $173.76 million, a PE ratio of -1.21 and a beta of 0.01. Karyopharm Therapeutics has a 12 month low of $0.62 and a 12 month high of $4.87. The stock has a 50-day moving average price of $1.26 and a two-hundred day moving average price of $1.05.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, February 29th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The business had revenue of $33.75 million during the quarter, compared to analysts’ expectations of $33.50 million. During the same period in the previous year, the company earned ($0.43) EPS. As a group, analysts predict that Karyopharm Therapeutics will post -1.15 earnings per share for the current fiscal year.

Insider Transactions at Karyopharm Therapeutics

In related news, CEO Richard A. Paulson sold 80,470 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $1.17, for a total transaction of $94,149.90. Following the completion of the sale, the chief executive officer now owns 1,183,783 shares of the company’s stock, valued at $1,385,026.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Michael Mason sold 27,687 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $1.17, for a total transaction of $32,393.79. Following the completion of the sale, the chief financial officer now owns 404,918 shares of the company’s stock, valued at $473,754.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Richard A. Paulson sold 80,470 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $1.17, for a total value of $94,149.90. Following the completion of the sale, the chief executive officer now directly owns 1,183,783 shares of the company’s stock, valued at approximately $1,385,026.11. The disclosure for this sale can be found here. Insiders sold 165,093 shares of company stock worth $196,952 over the last ninety days. 3.32% of the stock is owned by insiders.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of hedge funds have recently added to or reduced their stakes in KPTI. Bleakley Financial Group LLC purchased a new position in shares of Karyopharm Therapeutics during the second quarter valued at approximately $29,000. Advisor Group Holdings Inc. boosted its position in shares of Karyopharm Therapeutics by 134.3% during the fourth quarter. Advisor Group Holdings Inc. now owns 8,906 shares of the company’s stock valued at $30,000 after buying an additional 5,105 shares during the last quarter. Simplicity Solutions LLC purchased a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at approximately $33,000. Prelude Capital Management LLC purchased a new position in shares of Karyopharm Therapeutics during the second quarter valued at approximately $53,000. Finally, State of Wyoming boosted its position in shares of Karyopharm Therapeutics by 188.8% during the fourth quarter. State of Wyoming now owns 17,082 shares of the company’s stock valued at $58,000 after buying an additional 11,168 shares during the last quarter. Institutional investors and hedge funds own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).